2-(phenyl or heterocyclic)-1H-phenantrho[9,10-D]imidazoles as mPGES-1 inhibitors

Details for Australian Patent Application No. 2005316091 (hide)

Owner Merck Frosst Canada Ltd

Inventors Friesen, Richard; Chau, Anh; Yu, Hongping; Ducharme, Yves; Giroux, Andre; Gagnon, Marc; Frenette, Richard; Wu, Tom; Cote, Bernard; Martins, Evelyn

Agent Spruson & Ferguson

Pub. Number AU-B-2005316091

PCT Pub. Number WO2006/063466

Priority 60/637,180 17.12.04 US; 60/739,338 23.11.05 US

Filing date 15 December 2005

Wipo publication date 22 June 2006

Acceptance publication date 1 December 2011

International Classifications

C07D 235/02 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings

A61K 31/4164 (2006.01) - 1,3-Diazoles

A61K 31/4439 (2006.01)

C07D 401/04 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

Event Publications

21 June 2007 PCT application entered the National Phase

  PCT publication WO2006/063466 Priority application(s): WO2006/063466

1 December 2011 Application Accepted

  Published as AU-B-2005316091

29 March 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005316092-Upflow settling reactor for enzymatic hydrolysis of cellulose

2005316083-Concrete track for rail vehicles